InnoSIGN B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
InnoSIGN B.V. - overview
Established
2022
Location
Eindhoven, -, Netherlands
Primary Industry
Biotechnology
About
Based in Eindhoven, Netherlands, and founded in 2022, InnoSIGN B. V. is a precision medicine firm that focuses on diagnostics and drug development applications. It is a spin-out from Koninklijke Philips N.
V. In March 2022, InnoSIGN B. V. raised USD 8 million in Series A funding from Brabant Development Agency BOM, Casdin Capital, Life Science Angels, Inc.
, and Thuja Capital. Paul van de Wiel is the CEO of the company. The company provides OncoSIGNal pathway activity profiling technology, which is based on mRNA, which is transforming precision medicine by providing additional insight into disease causes. The firm utilizes its database with more than 100,000 pathway activity profiles to support diagnostics and drug development.
The March 2022 investment supports the organization's clinical validation and US market launch.
Current Investors
Thuja Capital, Life Science Angels, Inc., Casdin Capital
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.innosignbio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
InnoSIGN B.V. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.